Background: Cyclooxygenase-2 (COX-2) inhibitors have been found to be safe alternatives in adults with cross-intolerant hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs). However they are usually not prescribed in children and there is little information about their tolerance in the pediatric age group.
Objective: This study aims to evaluate the tolerance to etoricoxib in children with hypersensitivity to multiple antipyretics.
Methods: A retrospective case series of children diagnosed with hypersensitivity reactions to NSAIDs and/or paracetamol who underwent a drug provocation test (DPT) with etoricoxib. Information on atopy, family history of allergic diseases, and medication usage was collected. Outcomes of the DPTs and tolerance to etoricoxib were also evaluated.
Results: A total of 24 children, mean age 13.5 years, had a diagnosis of cross-intolerant hypersensitivity to NSAIDs and/or paracetamol. All except one patient successfully tolerated an oral challenge with etoricoxib. Of those who passed the DPT, the majority continued to use etoricoxib with no problems. It was found to be moderately effective in reducing fever and pain.
Conclusion: Etoricoxib can be used as a safe alternative in older children with hypersensitivity to multiple antipyretics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313751 | PMC |
| http://dx.doi.org/10.5415/apallergy.2015.5.1.40 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating potential unexpected adverse events and mortality after oral analgesics administration in fracture care-a cohort study.
Expert Opin Drug Saf
August 2024
Departments of Surgery, The Aga Khan University, Karachi, Pakistan.
Introduction: Analgesic selection per individual's tolerance is essential to avoid risks. The study evaluated current oral analgesic prescription practice, analgesic adverse effects-related factors, unexpected events, and mortality post-fracture surgery.
Research Design And Methods: The present prospective cohort study from June 2022 to July 2023 enrolled a total of 198 proximal femoral, ankle, and hindfoot trauma fracture patients.
Nimesulide-Induced Fixed Drug Eruption Followed by Etoricoxib-Induced Fixed Drug Eruption: An Unusual Case Report and Review of the Literature.
J Clin Med
March 2024
2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Article Synopsis
- A documented case highlights a patient who initially tolerated etoricoxib after a FDE from nimesulide but later developed an etoricoxib-induced FDE with severe symptoms.
- This suggests the need for more awareness in medicine regarding drug sensitivities and highlights the importance of further research to understand FDE mechanisms and improve diagnostics.
Nationwide Etoricoxib Injection Clinical Experience (NICE): Real-World Evidence in Indian Patients.
Cureus
February 2024
Medical Affairs, Zydus Lifesciences Ltd, Mumbai, IND.
Introduction Pain is a major health issue globally. Etoricoxib, a highly selective COX-2 inhibitor, given orally, has been found to be efficacious and safe in the management of acute and chronic pain. Oral etoricoxib has been extensively studied; however, there is a lack of research exploring the use of etoricoxib via alternative routes, specifically intramuscular (IM) injection.
View Article and Find Full Text PDFCase report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab.
Front Pharmacol
February 2024
Department of Internal Medicine III, Hematology and Oncology, University Hospital of Regensburg, Regensburg, Germany.
Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin's disease and significantly improved the proportion of patients with long-term disease control. However, there is no standardized therapeutic option in case of further progression. Recently, we demonstrated that therapy with MEPED (metronomic chemotherapy, everolimus, pioglitazone, etoricoxib, dexamethasone) is highly effective in patients with r/r Hodgkin's disease.
View Article and Find Full Text PDFEtoricoxib Coated Tablets: Bioequivalence Assessment between Two Formulations Administered under Fasting Conditions.
Pharmaceutics
November 2023
Clinical Research Unit, Medical Department, Adium S.A., São Paulo 04794-000, SP, Brazil.
Etoricoxib is a non-steroidal anti-inflammatory drug with high selectivity for cyclooxygenase 2 (COX-2), exerting a pronounced anti-inflammatory effect with fewer adverse events when compared to COX-1 inhibitors. The present study aimed to evaluate the bioequivalence between two etoricoxib-coated tablet formulations to meet regulatory requirements for a branded generic product registration in Brazil. A crossover study with an open-label, randomized design and a single-dose regimen with two treatments and two periods was conducted on healthy Brazilians of both genders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!